Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2014-11-04 Major Shareholding Noti…
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2014
Major Shareholding Notification
2014-11-04 English
OWNERSHIP DOCUMENT
Director's Dealing
2014-11-04 English
4
Director's Dealing
2014-11-03 English
3
Director's Dealing
2014-11-03 English
THERAVANCE, INC. 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The text includes multiple items: Item 2.02 reports results of operations and financial condition for the quarter ended September 30, 2014, with a press release attached as Exhibit 99.1. Item 5.02 announces changes in the board of directors and principal officers, including resignation and election of directors and appointment of chairman. Item 8.01 announces a cash dividend. The document is not a full financial report but a current report announcing multiple events including management changes and dividend declaration. The presence of board changes and dividend announcement points to multiple categories, but the primary content is management changes and related announcements. According to the filing definitions, announcements of changes in board or senior management fall under Board/Management Information (MANG). The dividend announcement is also present but secondary. The document is not a full earnings release (ER) or annual/interim report (10-K or IR). Therefore, the best classification is MANG with high confidence.
2014-10-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions an event on October 28, 2014, where GlaxoSmithKline presented clinical study data at a conference. The document includes a slide presentation as an exhibit but does not contain comprehensive financial data or detailed financial statements. The length is 3396 characters, which is relatively short and consistent with a current report rather than a full financial report. The content is about a clinical study presentation, not an earnings release, annual report, or other financial filing. Therefore, the document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like 8-Ks that do not fit other specific categories.
2014-10-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.